We suggest that the sequential use of in vitro testing of CFTR function in pHNECs and subsequent in vivo testing using biomarkers of CFTR function, in combination with clinical outcome measures, is a promising approach to facilitate access to CFTR modulator therapy and to enhance precision medicine for patients with CF carrying rare CFTR mutations. Here, CFTR is linked to cystic fibrosis.